Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis (APAT)

University Hospital of Bordeaux

Status

Enrolling

Conditions

Thrombocytopenia

Immune Thrombocytopenia

Myelodysplasia

Treatments

Biological: Blood samples

Study type

Interventional

Funder types

Other

Identifiers

NCT04800458

CHUBX 2020/61

Details and patient eligibility

About

Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the "monoclonal antibody immobilization of platelet antigens" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.

Enrollment

225 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patient over 18 years old;
Patients with thrombocytopenia <100 G/L, checked twice, having ruled out false thrombocytopenia by platelet aggregation and acute leukemia by smear;
No treatment started;
Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and prior to any review required by the research);
Person affiliated or benefiting from a social security scheme.

Exclusion criteria

Secondary ITP;
False thrombocytopenia;
Patients who have been transfused with platelets for less than 7 days with efficacy;
Patient treated for thrombocytopenia (48 hours of corticosteroid therapy is tolerated and is not an exclusion criteria);
Patient with acute leukemia;
Pregnant or breastfeeding woman;
False thrombocytopenia;
Patient under guardianship, curatorship or any other legal protection regime.